Skip to Content

Tag: Insulet


Also Noted

Insulet’s Omnipod fuels growth

February 23, 2024HME News Staff

ACTON, Mass. – Insulet reported full year 2023 revenues $1.7 billion, up 30% compared to 2022. Fourth quarter 2023 revenue was $509.8 million, up nearly 38%. Total Omnipod revenue was $501 million; of that, US Omnipod revenue was $394.6 million, an increase of nearly 43%. “2023 was another transformational year for Insulet,” said Jim Hollingshead, president & CEO. “The rapid adoption of Omnipod 5 helped fuel our eighth consecutive year of more than 20% constant currency revenue...

Diabetes, Insulet, Insulin pump, Omnipod


Read Full Articlered right arrow icon

Also Noted

Insulet gets FDA clearance for iPhone app

October 24, 2023HME News Staff

ACTON, Mass. – Insulet has received 510(k) clearance from the U.S. Food and Drug Administration for its Omnipod 5 App for iPhone, making Insulet the first company to offer a tubeless automated insulin delivery (AID) system with full control from a compatible Android and iOS smartphone. "Today, we celebrate this significant milestone in our ongoing effort to provide people with diabetes solutions that improve their lives and help them think less about diabetes," said Eric Benjamin, executive...

Diabetes, Insulet, Omnipod


Read Full Articlered right arrow icon

Also Noted

ResMed, AdaptHealth make tech list 

January 26, 2023HME News Staff

YARMOUTH, Maine – Several HME companies have made the Power 500 Technology Companies list, a nod to their commitment to improving the health of people around the world. In the Medical Devices category, ResMed, Dexcom, Insulet Corp., AdaptHealth and Masimo were all listed as leaders. The list includes companies that demonstrate product or service leadership, technical depth in their specific fields, consistent organizational growth or evolution, operational excellence and high-caliber management...

AdaptHealth, Dexcom, Insulet, Masimo, Power 500 Technology Companies, ResMed


Read Full Articlered right arrow icon

Also Noted

Insulet’s Omnipod 5 cleared for use ages two and up

August 24, 2022HME News Staff

ACTON, Mass. – Insulet has received U.S. Food and Drug Administration clearance for its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with Type 1 diabetes. “We received tremendous first-hand reports of how Omnipod 5 made diabetes management easier for our pivotal trial participants, and the clinical data demonstrated impressive glycemic improvements, as well,” said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet’s senior vice president and medical...

Diabetes, Insulet, Omnipod


Read Full Articlered right arrow icon

News

Earnings roundup: Great Elm, InfuSystem, Insulet 

May 9, 2022HME News Staff

WALTHAM, Mass. – Great Elm Group’s DME division grew total revenue by 19.2% to $15.6 million in the third quarter of fiscal year 2022, driven by strong resupply sales. The increase in revenue was primarily attributable to contributions from the previous acquisitions of AMPM in March 2021 and MedOne in August 2021. “Our investment in DME continues to perform well, despite challenging supply chain conditions,” said Peter Reed, CEO of Great Elm. The DME division reported a net...

Great Elm DME, InfuSystem, Insulet


Read Full Articlered right arrow icon

News

In brief: Invacare layoffs, Philips recall, ResMed exec

May 6, 2022HME News Staff

ELYRIA, Ohio – Invacare is streamlining its operations in the United States, primarily related to headcount reductions, to improve its cost structure, according to a May 4 filing with the U.S. Securities and Exchange Commission.  As a result, the company anticipates annual pre-tax savings of about $2.8 million, with about $1.9 million to be realized in 2022. It will incur restructuring charges of $800,000 and expects to make cash payments in the same amount, primarily related to...

CAIRE, Insulet, Invacare, Motion, Philips Recall, Quality Biomedical, ResMed, Rhythm Healthcare


Read Full Articlered right arrow icon

News

In brief: Inogen revenues, UnitedHealth merger, Heartland registration

February 25, 2022HME News Staff

GOLETA, Calif. – Inogen reported revenue of $76.4 million for the fourth quarter of 2021, an increase of 3.3% over the same period in 2020, driven by a 23.3% in domestic direct-to-consumer sales to $33 million.  Domestic business-to-business sales in the fourth quarter of 2021 decreased 57.6% to $10.3 million compared to $24.2 million in the fourth quarter of 2020, primarily due to the supply chain constraints that limited product availability in this channel.  Rental revenue...

AZ MediQuip, Heartland Conference, Inogen, Insulet, Sunrise Medical, UnitedHealth, VGM Group


Read Full Articlered right arrow icon

Also Noted

Insulet surpasses $1 billion in Omnipod revenue

February 25, 2022HME News Staff

ACTON, Mass. – Insulet Corporation reported revenue of $307.7 million for the fourth quarter of 2021, and full year revenue of $1.1 billion. Total Omnipod revenue was $275.8 million for the quarter and $1 billion for the full year. Of that, U.S. Omnipod revenue for the year was $651.5 million and international Omnipod revenue of $359.9 million. “2021 was another successful year for Insulet, as we reached an important milestone of over $1 billion in revenue and advanced our strategic priorities,”...

Diabetes, Insulet, Omnipod


Read Full Articlered right arrow icon

News

In brief: Woman of the Year finalists, supply chain relief, Quipt’s acquisition

November 12, 2021HME News Staff

WATERLOO, Iowa – The finalists for this year’s HME Woman of the Year are Trisha Bailey, CEO of Medical Hotspots/Bailey’s Medical; Neidi Mack, vice president for ancillary services at Prism Health Care Services/The Alden Network; Katie Stevens, CEO at Reliable Medical Supply; and Victoria Peterson, administrator at RespMed. “These HME Woman of the Year finalists are leaders in their companies and communities,” said Clint Geffert, president of VGM & Associates. “They...

Great Elm DME, HME Woman of The Year, Home Medical Equipment (HME), Insulet, Permobil, Quipt, VGM Group


Read Full Articlered right arrow icon

Specialty Providers

Insulet highlights ‘growing power’ of Omnipod

November 8, 2021HME News Staff

ACTON, Mass. – Insulet Corp. reported revenue of $275.6 million for the third quarter of 2021, up 17.8% over the same period last year.  It reported revenue was $260.3 million, up 22.7%, for Omnipod.  "Our third quarter results reflect the growing power of Omnipod,” said Shacey Petrovic, president and CEO. “We are driving global new customer starts, have momentum across our business, and are advancing exciting new innovations. We continue to share compelling clinical...

Diabetes, Insulet, Omnipod


Read Full Articlered right arrow icon